PI Trade Names and Active Ingredients containing Arixtra. 1 Documents available. Need more information on a product? Search the Australian Register of. Mylan manufactures ARIXTRA®* (fondaparinux sodium) Injection, Solution ( Arixtra) in strengths of 25 mg05 mL 5 mgmL5 mg04 mL mgmL75 mg06 mL injection of Arixtra mg in young healthy subjects are provided in Table 1 below: . Arixtra mg once daily following hip fracture surgery, patients were.
|Published (Last):||12 May 2006|
|PDF File Size:||18.92 Mb|
|ePub File Size:||7.4 Mb|
|Price:||Free* [*Free Regsitration Required]|
Patient should inform health care providers of anticoagulant therapy prior to having dental work performed.
Arixtra (fondaparinux sodium) dose, indications, adverse effects, interactions from
Arixttra patient should be closely monitored with frequent evaluation of the INR and clinical parameter, and the dosage of warfarin should be adjusted as necessary until a stable target INR is achieved. All patients should be evaluated for a bleeding disorder prior to administration of fondaparinux, unless the medication is needed urgently.
Related Drug Information Drug Summary. Coadministration of betrixaban and other anticoagulants may increase arxtra risk of bleeding. Unlike coumarins or heparinoids, an antidote to reverse bleeding with fondaparinux is not available. Moderate An additive risk of bleeding may be seen in patients receiving anticoagulants in combination with other agents known to increase the risk of bleeding such as nonsteroidal antiinflammatory drugs NSAIDs.
Moderate Monitor for evidence of bleeding if coadministration of dasatinib and anticoagulants is necessary. Fondaparinux use arixtrra labor or obstetric delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. Risk factors include those undergoing surgery with general anesthesia lasting more than 45 minutes who are 1 airxtra than 60 years or 2 more than 40 years with at least 1 of the following: Consider use of a shorter acting anticoagulant as delivery approaches.
Moderate Give the extended-release injectable suspension of naltrexone cautiously to patients taking anticoagulants. Avoid concurrent use of herbs which interact with warfarin when possible. The mechanism for bleeding with ibrutinib therapy is not well understood.
TGA eBS – Product and Consumer Medicine Information
This implies that a dose-related effect of fish oil on warfarin may be possible. The patient admitted that he had started consuming 0.
If garlic dietary supplements are taken, monitor the INR or other appropriate parameters to attain clinical and anticoagulant endpoints. Pentosan is a weak anticoagulant. All products differ in their manufacturing process, activity, and dosage.
Fulvestrant IM injections may cause bleeding, bruising, or hematomas in these patients. However, aspirin alone produced a marked inhibition of platelet aggregation ex vivo; anagrelide enhanced the platelet inhibition effects of aspirin slightly.
Moderate Due to the risk of bleeding with natural antineoplastics, patients should receive other agents that may increase the risk of bleeding, such as anticoagulants.
Bismuth Subsalicylate; Metronidazole; Tetracycline: Patients may be at increased risk of bleeding if anagrelide is administered with aspirin.
Other intramuscular injections should be administered cautiously to patients receiving fondaparinux. Heparin-induced thrombocytopenia HITthrombocytopenia. Major Discontinue pentosan before starting fondaparinux due to the increased bleeding risk, unless these agents are essential. Major Ginkgo, Aritxra biloba is reported to inhibit platelet aggregation and several case reports describe bleeding complications with Ginkgo biloba, with or without concomitant drug therapy.
Thus, patients receiving anticoagulation due to a history of these conditions are not candidates for prasterone treatment. Administration before 6 hours after surgery has been associated with an increased risk of major bleeding. Fondaparinux exhibits dose-dependent, linear pharmacokinetics.
If possible, agents that enhance the risk of arixfra should be discontinued prior to initiation of fondaparinux therapy.
It is possible that the use of green arixtr may increase the risk of bleeding if co-administered with anticoagulants e. It would be prudent for clinicians to monitor the INR and clinical status of the patient closely if vilazodone is added to or removed from the regimen of a patient stabilized on warfarin. To minimize bleeding risk, fondaparinux injection should be administered according to the recommended dosage regimen for peri-operative prophylaxis see Dosage ; administration before 6 hours after surgery has been associated an increased risk of major bleeding.
Moderate Because dipyridamole is a platelet inhibitor, there is a potential additive risk for bleeding if dipyridamole is given in combination with other agents that affect hemostasis.